Combination of interferon with tyrosine kinase inhibitor

Important notice: You must inform your CML doctor or a qualified doctor before using this drug. The material presented here is for information purposes only;  it is not a substitute for your physician’s guidance and care. ​            

VIDEOS


Dr. Hochhaus on TFS With Nilotinib in Patients With CML
June 3, 2016, OncLiveTV

Prof Andreas Hochhaus: Welt-CML-Tag und TIGER-Studie
October 4, 2012, Jan Geissler
​​

CLINICAL TRIALS

Phase II study of nilotinib plus pegylated interferon alfa-2b as first-line therapy in chronic phase chronic myeloid leukaemia aiming to maximize complete molecular response and major molecular response
April 9, 2018, Australian New Zealand  Clinical Trials Registry

Tasigna and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study (TIGER)
August 22, 2017,  ClinicalTrials.gov

 
ARTICLES


Peg-Interferon Αlpha 2b can improve molecular recurrences in the  TREATMENT-FREE REMISSION; A pilot study with 18-month follow-up
June 2018, EHA 2018

Nilotinib in Combination with Pegylated Interferon Alfa-2b for CP-CML Leads to High Molecular Response Rates: Interim Results of the Pinnacle Study
2017, ASH2017
​
Nilotinib Versus Nilotinib Combined to Pegylated-Interferon Alfa 2a in First-Line Chronic Phase Chronic Myelogenous Leukemia Patients. Interim Analysis of a Phase III Trial
2017, ASH2017

Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia
February 25, 2015, Leukemia

Tyrosine Kinase Inhibitors and Interferon
January 2 , 2014, NCBI   

Re-emergence of interferon-α in the treatment of chronic myeloid leukemia
December 14, 2012, Leukemia

Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia
December 23, 2010, The New England Journal of Medicine

                                         ​            
                                        Return to Cure possible for  CML?